Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 83NIH 53NETWORK 4INDUSTRY 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1CNS 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 2Melanoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × CTLA-4 Antigen × Clear all
NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 2 Recruiting
112 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT02785952 2025-05-21

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

SWOG Cancer Research Network

Phase 3 Active not recruiting
275 enrolled 15 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡